SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 351 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,828,438 | +2.0% | 130,565 | -3.7% | 0.03% | +3.3% |
| Q2 2023 | $15,523,600 | -28.8% | 135,565 | -14.3% | 0.03% | -30.2% |
| Q1 2023 | $21,800,155 | +8.0% | 158,167 | +1.5% | 0.04% | +2.4% |
| Q4 2022 | $20,189,211 | +25.4% | 155,805 | +6.9% | 0.04% | +20.0% |
| Q3 2022 | $16,106,000 | +141.6% | 145,741 | +63.8% | 0.04% | +150.0% |
| Q2 2022 | $6,666,000 | -13.0% | 88,948 | -9.3% | 0.01% | +7.7% |
| Q1 2022 | $7,662,000 | -3.4% | 98,116 | +11.4% | 0.01% | 0.0% |
| Q4 2021 | $7,928,000 | +192.8% | 88,056 | +200.6% | 0.01% | +160.0% |
| Q3 2021 | $2,708,000 | +6.2% | 29,298 | -10.7% | 0.01% | +25.0% |
| Q2 2021 | $2,549,000 | -7.0% | 32,812 | -11.0% | 0.00% | -20.0% |
| Q1 2021 | $2,741,000 | +0.5% | 36,884 | +130.5% | 0.01% | 0.0% |
| Q4 2020 | $2,727,000 | +20.1% | 16,000 | -1.1% | 0.01% | 0.0% |
| Q3 2020 | $2,270,000 | -18.0% | 16,171 | -6.2% | 0.01% | -16.7% |
| Q2 2020 | $2,768,000 | +76.8% | 17,244 | +7.8% | 0.01% | +50.0% |
| Q1 2020 | $1,566,000 | -27.2% | 15,997 | -4.2% | 0.00% | 0.0% |
| Q4 2019 | $2,152,000 | +91.5% | 16,697 | +11.9% | 0.00% | +100.0% |
| Q3 2019 | $1,124,000 | -47.2% | 14,928 | +6.5% | 0.00% | -50.0% |
| Q2 2019 | $2,130,000 | +8.7% | 14,013 | -14.7% | 0.00% | 0.0% |
| Q1 2019 | $1,959,000 | +19.5% | 16,426 | +9.3% | 0.00% | 0.0% |
| Q4 2018 | $1,640,000 | -41.2% | 15,027 | -13.0% | 0.00% | -20.0% |
| Q3 2018 | $2,789,000 | -57.5% | 17,269 | -65.2% | 0.01% | -64.3% |
| Q2 2018 | $6,567,000 | +68.6% | 49,667 | -5.5% | 0.01% | +100.0% |
| Q1 2018 | $3,894,000 | +24.8% | 52,543 | -4.6% | 0.01% | +40.0% |
| Q4 2017 | $3,119,000 | -15.5% | 55,089 | -32.3% | 0.01% | -16.7% |
| Q3 2017 | $3,693,000 | +45.7% | 81,410 | +8.3% | 0.01% | +50.0% |
| Q2 2017 | $2,534,000 | +123.7% | 75,170 | +96.4% | 0.00% | +100.0% |
| Q1 2017 | $1,133,000 | +75.7% | 38,273 | +63.9% | 0.00% | +100.0% |
| Q4 2016 | $645,000 | – | 23,354 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 2,878,979 | $69,182,000 | 7.27% |
| Eventide Asset Management | 259,100 | $6,226,000 | 0.97% |
| GLADE BROOK CAPITAL PARTNERS LLC | 251,000 | $6,032,000 | 0.93% |
| IMS Capital Management | 32,215 | $774,000 | 0.91% |
| Perceptive Advisors | 350,000 | $8,413,000 | 0.88% |
| Benchmark Capital Advisors | 34,900 | $839,000 | 0.58% |
| BECK CAPITAL MANAGEMENT, LLC | 24,744 | $636,000 | 0.49% |
| SABBY MANAGEMENT, LLC | 352,100 | $8,461,000 | 0.47% |
| Hatteras Alternative Mutual Funds, LLC | 39,404 | $947,000 | 0.46% |
| Potomac Capital Management, Inc. | 22,100 | $531,000 | 0.45% |